Publisher
Springer Science and Business Media LLC
Subject
Obstetrics and Gynecology,Oncology
Reference7 articles.
1. International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012.
http://globocan.iarc.fr/Pages/bar_sex_pop_sel.aspx
.
2. De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol. 2014;15:23–34.
3. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–83.
4. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–96.
5. Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab or women with newly diagnosed ovarian cancer (ICON7):overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16:928–36.